Drug Profile
LY 3164530
Alternative Names: LY3164530Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
- Mechanism of Action Epidermal growth factor receptor antagonists; Proto-oncogene protein c-met inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Cancer(Metastatic disease, Second-line therapy or greater) in USA (IV, Infusion)
- 07 Mar 2017 Eli Lilly completes a phase I trial for Cancer (Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT02221882)
- 14 Apr 2016 Pharmacodynamics data from a preclinical trial in Cancer presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)